Lilly’s fourth-quarter earnings, released before the market opened Thursday, surpassed analysts’ expectations by millions.
Read More
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Read More
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic leaders say the project is a huge success, but some political leaders are cautious.
Read More
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and Drug Administration granted a breakthrough device designation to the product.
Read More
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
The company expects fourth-quarter revenue to be about $13.5 billion.
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $972 and announcements about big new investments in Lebanon and Ireland.
Lilly said the expansion is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
The ongoing progress to develop the planned LEAP Innovation and Research District, a 9,000-acre tech park in Boone County, was among the top local tech stories of 2024.
Lilly’s stock was up slightly in after-hours trading.
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
The state will eventually recoup much of that investment when LEAP land is sold to tenants, officials from the Indiana Economic Development Corp. said.
The state’s job-creation agency is seeking $27 million to purchase about 307 acres and pay for deposits and option payments for additional land west of Interstate 65. Another $33 million is being sought for infrastructure work.
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Lilly also approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro.
Under pressure to keep up with soaring demand for drug treatments for obesity, diabetes and other diseases, Eli Lilly and Co. is planning its single largest U.S. manufacturing investment outside of Indiana.
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
While the proposed rule would give millions of people access to weekly injectables like Eli Lilly and Co.’s Zepbound that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.
